<DOC>
	<DOCNO>NCT00715208</DOCNO>
	<brief_summary>This phase 2 , two-arm , non-randomized , open-label , multicenter study evaluate safety efficacy 2 VELCADE-containing regimen . Patients treat either combination VELCADE , rituximab , cyclophosphamide , doxorubicin , prednisone ( VELCADE-R-CAP ) combination VELCADE , rituximab , cyclophosphamide , prednisone ( VELCADE-R-CP ) base investigator preference . Following completion treatment period , patient receive maintenance therapy rituximab maximum 2 year .</brief_summary>
	<brief_title>Phase 2 Study VELCADE ( Bortezomib ) Patients With Relapsed Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Male female patient 18 year age old Pathological diagnosis follicular lymphoma ( grade ) marginal zone lymphoma . Patients transform follicular lymphoma eligible , provide previously pathologic documentation follicular lymphoma . Documented relapse progression follow prior antineoplastic therapy At least 1 measurable tumor mass great 1.5 cm long axis great 1.0 cm short axis previously irradiate , grow since previous irradiation No clinically significant evidence active central nervous system lymphoma Karnofsky performance status ( KPS ) ≥50 ( equivalent Eastern Cooperative Group Oncology Group [ ECOG ] status ≤2 ) Diagnosed treated malignancy NonHodgkin 's Lymphoma ( NHL ) within 2 year first dose , previously diagnose malignancy NHL radiographic biochemical marker evidence malignancy . Patients prostate cancer treat definitive radiotherapy serum prostatespecific antigen &lt; 1 ng/mL exclude . Patients exclude basal cell squamous cell carcinoma skin completely resect , situ malignancy adequately treat . Received follow treatment procedure outside specify timeframes : Prior treatment VELCADE Prior treatment cumulative dose doxorubicin 100 mg/m2 , assign Arm A ( VELCADERCAP ) Antineoplastic ( include unconjugated therapeutic antibody toxin immunoconjugates ) , experimental , radiation therapy within 3 week Day 1 Cycle 1 Nitrosoureas within 6 week Day 1 Cycle 1 Radioimmunoconjugates within 10 week Day 1 Cycle 1 Autologous stem cell transplant within 3 month Day 1 Cycle 1 , prior allogeneic stem cell transplant time Major surgery within 2 week Day 1 Cycle 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>